Meanwhile, the anti-tumor activity of PD-1 deficient GPC3-CAR T cells against GPC3-negative SK-HEP-1 HCC cells was limited (<5%) and similar to that of UTD and wild-type GPC3-CAR T cells, indicating that the disruption of PD-1 did not affected the cytotoxic specificity of GPC3-CAR T cells. This evidence concerns the gene GPC3 and neoplasm.